Head to head

Sermorelin vs Tesamorelin

Two peptides on the same pathway, separated mostly by how modern and how regulated each is. A useful factual comparison for anyone logging GH-axis compounds.

The short answer. Both are GHRH analogs (growth-hormone-releasing peptides), and the main differences are stability and regulatory status: tesamorelin is a stabilized analog with an FDA-approved indication, while sermorelin is the older, shorter-acting GHRH fragment.

Side by side

 SermorelinTesamorelin
ClassPeptidesPeptides
FormInjectionInjection
Half-life≈ 12 minutes≈ 30 minutes
Storage
Dose unitsmcg, mgmg
FDA statusApprovedApproved

Facts from the Stack compound library. See the full pages: Sermorelin · Tesamorelin.

How they differ

Molecule

Sermorelin is a fragment of GHRH (the first 29 amino acids). Tesamorelin is a stabilized GHRH analog engineered for a longer functional life.

Approval

Tesamorelin has a specific FDA-approved indication; sermorelin's regulatory history is different. Each page states its status — read them rather than assuming.

Cadence

Both are injectable peptides reconstituted from powder, so the calculator, refrigeration and opened-vial dates apply to each.

Tracking

GH-axis peptides reward careful timing logs; record the dose, time and site each administration.

Tracking either one

Whichever you log, the workflow is the same in Stack: add it once, set the schedule, and let the app handle reminders, supply projection and an "in your system" curve from the half-life. Run both? Group them into one protocol you can pause together.

Track your stack in Stack

Free to track — doses, schedules, supply and reminders in one quiet app. Your health data stays encrypted on your device.

Get the app
Not medical advice. This page compares publicly-documented properties of two compounds for educational purposes. It does not recommend either one, or any dose. How we source →

Last reviewed 2026-06-11